Your browser doesn't support javascript.
loading
Sanguinarine metabolism and pharmacokinetics study in vitro and in vivo.
Wu, Yong; Zhao, Na-Jiao; Cao, Yan; Sun, Zhuo; Wang, Qin; Liu, Zhao-Ying; Sun, Zhi-Liang.
Afiliação
  • Wu Y; Hunan Engineering Technology Research Center of Veterinary Drugs, College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
  • Zhao NJ; Hunan Engineering Technology Research Center of Veterinary Drugs, College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
  • Cao Y; Hunan Engineering Technology Research Center of Veterinary Drugs, College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
  • Sun Z; Hunan Engineering Technology Research Center of Veterinary Drugs, College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
  • Wang Q; Hunan Engineering Technology Research Center of Veterinary Drugs, College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
  • Liu ZY; Hunan Engineering Technology Research Center of Veterinary Drugs, College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
  • Sun ZL; Hunan Engineering Technology Research Center of Veterinary Drugs, College of Veterinary Medicine, Hunan Agricultural University, Changsha, China.
J Vet Pharmacol Ther ; 43(2): 208-214, 2020 Mar.
Article em En | MEDLINE | ID: mdl-31943246
ABSTRACT
Sanguinarine (SA) is a benzo[c] phenanthridine alkaloid which has a variety of pharmacological properties. However, very little was known about the pharmacokinetics of SA and its metabolite dihydrosanguinarine (DHSA) in pigs. The purpose of this work was to study the intestinal metabolism of SA in vitro and in vivo. Reductive metabolite DHSA was detected during incubation of SA with intestinal mucosa microsomes, cytosol, and gut flora. After oral (p.o.) administration of SA, the result showed SA might be reduced to DHSA in pig intestine. After i.m. administration, SA and DHSA rapidly increased to reach their peak concentrations (Cmax , 30.16 ± 5.85, 5.61 ± 0.73 ng/ml, respectively) at 0.25 hr. Both compounds were completely eliminated from the plasma after 24 hr. After single oral administration, SA and DHSA rapidly increased to reach their Cmax (3.41 ± 0.36, 2.41 ± 0.24 ng/ml, respectively) at 2.75 ± 0.27 hr. The half-life (T1/2 ) values were 2.33 ± 0.11 hr and 2.20 ± 0.12 hr for SA and DHSA, respectively. After multiple oral administration, the average steady-state concentrations (Css ) of SA and DHSA were 3.03 ± 0.39 and 1.42 ± 0.20 ng/ml. The accumulation indexes for SA and DHSA were 1.21 and 1.11. The work reported here provides important information on the metabolism sites and pharmacokinetic character of SA. It explains the reasons for low toxicity of SA, which is useful for the evaluation of its performance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Suínos / Benzofenantridinas / Isoquinolinas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Suínos / Benzofenantridinas / Isoquinolinas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article